Skip to content
10-Q

Quarterly Report

ATYR PHARMA, INC. ATYR

0000950170-25-065640

← back to feed
Filed
May 7, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 2, 2025 89M sh
Stockholders Equity Q1 2025 · Mar 31, 2025 $75.05M
Stockholders Equity Q1 2025 · Dec 31, 2024 $70.02M
Current Liabilities Q1 2025 · Mar 31, 2025 $10.68M
Current Liabilities Q1 2025 · Dec 31, 2024 $14.97M
Current Assets Q1 2025 · Mar 31, 2025 $83.27M
Current Assets Q1 2025 · Dec 31, 2024 $81.95M
Total Assets Q1 2025 · Mar 31, 2025 $97.25M
Total Assets Q1 2025 · Dec 31, 2024 $96.83M
Revenue Q1 2025 · Mar 31, 2025 $0
Revenue Q1 2025 · Mar 31, 2024 $235K
Cash And Equivalents Q1 2025 · Dec 31, 2024 $11.06M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $6.81M
Shares Diluted Q1 2025 · Mar 31, 2024 66.08M sh
Capex Q1 2025 · Mar 31, 2024 $17K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$22.38M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.23
Eps Basic Q1 2025 · Mar 31, 2024 −$0.23
Sga Expense Q1 2025 · Mar 31, 2024 $3.51M
Rd Expense Q1 2025 · Mar 31, 2024 $13.36M
Net Income Q1 2025 · Mar 31, 2024 −$15.49M
Operating Income Q1 2025 · Mar 31, 2024 −$16.64M